On April 8, 2025, Cartesian Therapeutics announced positive 12-month efficacy and safety data from its Phase 2b trial of Descartes-08 for generalized myasthenia gravis, showing sustained symptom improvement in participants. The trial reported an average MG-ADL score reduction of 5.5 at Month 4 and 4.8 at Month 12, with 83% of participants maintaining a clinically meaningful response.